# EDGAR Filing Document

**Accession Number:** 0001817241
**File Stem:** 0001193125-25-180011
**Filing Date:** 2025-8
**Character Count:** 2837
**Document Hash:** 93d8b304238d99ff9dc18393fac2911f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-180011.hdr.sgml**: 20250915

**ACCESSION NUMBER**: 0001193125-25-180011

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250813

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Artiva Biotherapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001817241
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 863614316
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 5505 MOREHOUSE DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** (858) 267-4467

**MAIL ADDRESS:**
- **STREET 1:** 5505 MOREHOUSE DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**ARTIVA BIOTHERAPEUTICS, INC.** 

5505 Morehouse Drive, Suite 100

San Diego CA 92121

August 13, 2025

***VIA EDGAR*** 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Tim Buchmiller

---

| | |
|:---|:---|
| Re: | **Artiva Biotherapeutics, Inc.** |

---

**Registration Statement on Form S-3 (File No. 333-289325)**

**Filed: August 6, 2025** 

**Request for Acceleration of Effective Date** 

Dear Mr. Buchmiller,

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the "***Registrant***") hereby requests that the Securities and Exchange Commission (the "***Commission***") take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-289325) (the "***Registration Statement***") to become effective on August 15, 2025, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such other time as the Registrant or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. The Registrant hereby authorizes each of Carlos Ramirez and Christine S. Kim of Cooley LLP to make such a request on its behalf.

Once the Registration Statement has been declared effective, please confirm that event with Carlos Ramirez of Cooley LLP at (858) 550-6157 or cramirez@cooley.com, or in his absence, Christine S. Kim at (858) 550-6110 or cskim@cooley.com.

---

| | |
|:---|:---|
|  Very truly yours, | Very truly yours, |
|  Artiva Biotherapeutics, Inc. | Artiva Biotherapeutics, Inc. |
|  By: | /s/ Fred Aslan, M.D. |
|  | Fred Aslan, M.D. |
|  | *President and Chief Executive Officer* |

---

---

| | |
|:---|:---|
| cc: | Neha Krishnamohan, Artiva Biotherapeutics, Inc. |
|  | Jennifer Bush, Artiva Biotherapeutics, Inc. |
|  | Andrew Cronauer, Artiva Biotherapeutics, Inc. |
|  | Carlos Ramirez, Cooley LLP |
|  | Christine S. Kim, Cooley LLP |

---